Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy

Citations Over TimeTop 1% of 2005 papers

Abstract

Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of nonadjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with seroconversion rates to A/HongKong/156/97, A/HongKong/213/03, A/Thailand/16/04, and A/Vietnam/1203/04 of 100% (P < .0001), 100% (P < .0001), 71% (P = .0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5.

Related Papers

• → Comparing introduction to Europe of highly pathogenic avian influenza viruses A(H5N8) in 2014 and A(H5N1) in 2005(2014)76 cited
• → Backyard Poultry Mortality Associated with Highly Pathogenic Avian Influenza (HPAI) H5N1 outbreaks in Nigeria(2014)7 cited
• → Features of Highly Pathogenic Avian Influenza (HPAI) H5N1 in Domestic Poultry(2020)4 cited
• → Evaluating a surveillance system: live-bird market surveillance for highly pathogenic avian influenza, a case study(2014)4 cited
• → Spatial and temporal analyses of highly pathogenic avian influenza H5N1 re-emergence in Nigeria, 2015(2018)